Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06982352 · ClinicalTrials.gov registry record · Phase 1

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

A Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO), sponsored by LAPIX Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
3
Study locations

NCT06982352 is a Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO) that is actively recruiting participants, run by LAPIX Therapeutics. The registered enrollment target is 48 participants, below the 104-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (54% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06982352, a Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO), is actively recruiting participants, sponsored by LAPIX Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.

Conditions Studied

Atopic Dermatitis (AD) Psoriasis (PsO)

Interventions

  • DRUG Placebo
  • DRUG LPX-TI641

Study Locations (3)

North Dakota

  • Red River Research Partners - Fargo

Texas

  • Clinical Investigations of Texas - Dallas

Jordan

  • Triumpharma Clinical Research Unit at AlEssra Hospital - Amman

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-06-15
Est. Completion 2026-04-15
Phase Phase 1

Sponsor

LAPIX Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06982352

The ClinicalTrials.gov registry entry for NCT06982352 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (54% lower). The listed sponsor is LAPIX Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06982352 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Dakota, Texas, Jordan.

Frequently Asked Questions

What is clinical trial NCT06982352 about?

NCT06982352 is a clinical study titled "Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis". The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI6...

What is the current status of trial NCT06982352?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-06-15. Estimated completion is 2026-04-15.

What conditions does trial NCT06982352 study?

This clinical trial studies the following conditions: Atopic Dermatitis (AD), Psoriasis (PsO).

What interventions are being tested in trial NCT06982352?

The interventions under investigation include: Placebo (DRUG), LPX-TI641 (DRUG).

Who is sponsoring clinical trial NCT06982352?

This trial is sponsored by LAPIX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06982352 being conducted?

This trial has 3 study locations across North Dakota, Texas, Jordan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis (AD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis (AD)

All registered trials for this condition

Psoriasis (PsO)

All registered trials for this condition

North Dakota

All trials with a study site in North Dakota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.